Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Collaboration › Details

Fluidigm–UBS: investor conference, 201905 supply service Fluidigm presents at UBS Global Healthcare Conference NY

	Period	2019-05-21
	Region	New York, NY
	Country	United States (USA)
	Partner, 1st	Fluidigm Corporation (Nasdaq: FLDM)
	Group	Fluidigm (Group)
	Product	UBS Global Healthcare Conference 2019 New York
	Product 2	CyTOF® mass cytometer
	Person	Linthwaite, S. Christopher (Chris) (Fluidigm 201610– CEO joined 201608 as COO before Thermo Fisher + Life Technologies)
	Person 2	Lee, Agnes (Fluidigm 201806 VP Investor Relations)

Fluidigm Corporation. (5/9/19). "Press Release: Fluidigm to Participate in Upcoming Health Care Investor Conferences". South San Francisco, CA.

Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor conferences.

> Chris Linthwaite, President and Chief Executive Officer, will participate in a fireside chat regarding Fluidigm’s business strategy and financial performance on Tuesday, May 21, 2019 at 11:30 ET at the UBS Global Healthcare Conference in New York.

> Vikram Jog, Chief Financial Officer, is scheduled to present on Tuesday, June 4, 2019, at 1:30 pm ET regarding Fluidigm’s business strategy and financial performance at the Jefferies 2019 Healthcare Conference in New York. A breakout will follow the presentation at 2:00 pm ET.

A live webcast of the company’s fireside chat, presentation and subsequent replay will be available in the Events & Presentations section of the Company’s investor website. The webcast will be available one hour after the conclusion of the events and will be archived for 90 days following the live presentation.

About Fluidigm

Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Fluidigm and the Fluidigm logo are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Contact:

Fluidigm Corporation

Agnes Lee
Vice President, Investor Relations
650 416 7423
agnes.lee@fluidigm.com